Skipping the FSH-stimulated cycle usually results in a shorter time to pregnancy.
Skipping over the gonadotropin-stimulated artificial insemination cycles that usually precede in vitro fertilization (IVF) attempts results in a shorter time to pregnancy and less expense, as well as a lower risk for multiple births, according to the results of a recent randomized clinical trial.
The FASTT (the Fast Track and Standard Treatment Trial) included just over 500 couples with unexplained infertility. Approximately one half of the couples were treated conventionally with three cycles of clomiphene citrate (CC)/IUI, three cycles of gonadotropin/intrauterine stimulation (FSH/IUI), and up to six cycles of IVF, while the other half followed an accelerated protocol that omitted the three cycles of FSH/IUI.
Pregnancy was achieved about 25% faster in the accelerated group. Those couples became pregnant in an average of 8 months, compared with 11 months for the couples in the conventional arm of the study. And, on average, couples in the accelerated arm accumulated almost $10,000 less in total pregnancy and delivery charges than those in the conventional arm, partly because of the direct savings associated with foregoing the FSH/IUI, but also by greatly reducing the increased charges associated with multiple pregnancies and births.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More